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NSW, AustraliaA B S T R A C TObjective: To assess the cost-effectiveness of sensor-augmented
insulin pump therapy with “Low Glucose Suspend” (LGS) functionality
versus standard pump therapy with self-monitoring of blood glucose
in patients with type 1 diabetes who have impaired awareness of
hypoglycemia. Methods: A clinical trial–based economic evaluation
was performed in which the net costs and effectiveness of the two
treatment modalities were calculated and expressed as an incremen-
tal cost-effectiveness ratio (ICER). The clinical outcome of interest for
the evaluation was the rate of severe hypoglycemia in each arm of the
LGS study. Quality-of-life utility scores were calculated using the
three-level EuroQol ﬁve-dimensional questionnaire. Resource use
costs were estimated using public sources. Results: After 6 months,
the use of sensor-augmented insulin pump therapy with LGS signiﬁ-
cantly reduced the incidence of severe hypoglycemia compared with
standard pump therapy (incident rate difference 1.85 [0.17–3.53]; P ¼
0.037). Based on a primary randomized study, the ICER per severeee front matter Copyright & 2014, International S
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h, WA 6840, Australia.hypoglycemic event avoided was $18,257 for all patients and $14,944
for those aged 12 years and older. Including all major medical
resource costs (e.g., hospital admissions), the ICERs were $17,602
and $14,289, respectively. Over the 6-month period, the cost per
quality-adjusted life-year gained was $40,803 for patients aged 12
years and older. Conclusions: Based on the Australian experience
evaluating new interventions across a broad range of therapeutic
areas, sensor-augmented insulin pump therapy with LGS may be
considered a cost-effective alternative to standard pump therapy with
self-monitoring of blood glucose in hypoglycemia unaware patients
with type 1 diabetes.
Keywords: cost-effectiveness, hypoglycemia, insulin pump therapy,
type 1 diabetes.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Around 120,000 Australians require daily exogenous insulin deliv-
ery to treat the autoimmune chronic condition, type 1 diabetes [1].
Achieving blood glucose control by minimizing hyperglycemia and
hypoglycemia [2] is essential for effectively managing type 1
diabetes because stringent blood glucose control is associated with
reductions in microvascular and macrovascular complication rates[2,3]. Continuous subcutaneous insulin infusion, otherwise known
as insulin pump therapy, is an intensive insulin regime used in
conjunction with self-monitoring of blood glucose (SMBG) to effec-
tively achieve strict glycemic (glucose) control in these patients.
This type of therapy is currently used by approximately 10% of the
patients with type 1 diabetes in Australia—almost half of whom are
younger than 25 years [4]. Unfortunately, an acute complication of
intensive insulin therapy is the increased risk of hypoglycemia [3].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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with no continuous glucose monitoring. In general, insulin is
given continuously by predetermined basal rates. Patients also
give insulin boluses on the basis of carbohydrate control of meals
and meter blood glucose levels. There is no warning system
within these standard pumps that alerts the user to impending
hypoglycemia. Hypoglycemia must therefore be detected by
intermittent ﬁnger-stick glucose tests and treated by increased
glucose intake. In Australia, the use of continuous glucose
monitoring with standard pump therapy is not yet standard
of care.
Although mild hypoglycemia is common to all insulin-treated
individuals with type 1 diabetes, some individuals frequently
experience severe hypoglycemic events. Severe hypoglycemia is a
serious and much feared complication of type 1 diabetes, and it is
considered the main barrier to improving and achieving glycemic
targets [5,6]. The potential consequences of recurrent severe
hypoglycemia include adverse psychosocial and socioeconomic
effects, seizures, permanent brain damage/cognitive impairment,
and death [3,7–9]. In attempting to avoid hypoglycemia, patients
and carers sometimes target higher blood glucose levels [10],
which increases the risk of long-term microvascular and macro-
vascular complications [11].
A major challenge in managing type 1 diabetes is impaired
awareness of hypoglycemia. When this develops, symptoms of
hypoglycemia change and become more subtle [2]. Impaired
awareness of hypoglycemia is more common in people who have
lived with diabetes for 10 or more years [2]. Impaired awareness
of hypoglycemia occurs in about 29% of people with type 1
diabetes (both children and adults), exposing them to increased
risk of severe hypoglycemic events [2,12]. In people with reduced
hypoglycemic awareness, increased vigilance with blood glucose
monitoring is required to prevent severe hypoglycemia [2].
Australian experts, along with international guidance and
consensus statements, recommend that real-time continuous
glucose monitoring (RT-CGM) be considered in patients who are
hypoglycemia unaware [2,13,14]. The use of RT-CGM with an
insulin pump that features automated insulin suspension, that
is, Low Glucose Suspend (LGS) pump, can further assist in
avoiding hypoglycemia and improving epinephrine responses to
hypoglycemia in patients with reduced hypoglycemic awareness
[15]. The LGS feature is an insulin suspension mechanism that
automatically stops insulin delivery for up to 2 hours when a
patient’s sensor glucose levels reach a preset low threshold and
he or she has not responded to the pump’s alarms.
In this study, the cost-effectiveness of LGS pump versus
standard pump with SMBG (ﬁnger-prick testing) was assessed
from an Australian health care system perspective on the basis
of a randomized study of patients with type 1 diabetes and
impaired hypoglycemia awareness. Third-party payers and policy-
makers seek evidence that the proposed sensor-augmented pump
therapy with automatic insulin suspension offers a cost-effective
alternative to standard pump therapy in this high-risk population.Methods
Participants and Comparisons
A systematic literature review of MEDLINE, EMBASE, and Cochrane
databases was conducted in December 2012, along with the Med-
tronic internal clinical studies database to identify available
randomized studies of LGS pump versus standard pump in patients
with impaired hypoglycemia awareness. This patient population
was chosen because the automated insulin suspension technology
in conjunction with the sensor is of particular relevance in this
high-risk patient population. Importantly, this combined technologyallows full functionality of the integrated RT-CGM pump system to
be used, enabling insulin suspension when the glucose level reaches
a minimum threshold preset by the patient/carer and his or her
health care professional to prevent hypoglycemic episodes. No
studies were identiﬁed in the published literature, yet one available
study was identiﬁed in the company database. This study has
subsequently been published, and the authors kindly provided full
access to the clinical study data [16]. Four nonrandomized suppor-
tive studies [17–22] were identiﬁed in the literature, although these
were not used in the economic modeling.
This economic evaluation is based on the only randomized
study comparing sensor-augmented insulin pump therapy with
LGS (Medtronic Paradigm Veo System, Medtronic Minimed, North-
ridge, CA) with standard pump-only therapy and SMBG [16]. The
study enrolled children (n ¼ 31), adolescents (n ¼ 34), and adults
(n ¼ 30) aged between 4 and 50 years (mean age 18.6  11.8 years)
who had type 1 diabetes, were established pump users (mean 4.0
 3.3 years), and had documented impaired awareness of hypo-
glycemia. Patients with impaired awareness of hypoglycemia were
identiﬁed using a modiﬁed version of the validated Clarke’s
questionnaire, which is a validated instrument for measuring this
characteristic [23]. The modiﬁed version removed two questions,
rephrased two questions, and converted units to SI units, and is
therefore not validated in its current form. Participants had a
mean duration of diabetes of 11.0  8.9 years and were treated in
two tertiary hospitals in Perth, Western Australia [16]. The efﬁcacy
results have been reported elsewhere [16]. Participants were
randomized to receive sensor-augmented insulin pump therapy
with automated insulin suspension (LGS pump, n ¼ 46) or stand-
ard pump therapy and SMBG (standard pump, n ¼ 49) and were
followed for a period of 6 months. Randomization was computer-
generated and stratiﬁed by age [16]. The two groups had similar
baseline characteristics [16]. The patients enrolled in the clinical
study are consistent with a population with type 1 diabetes who
have impaired hypoglycemia awareness and likely users of the
technologies assessed. The study recorded information on the
incidence of hypoglycemia and information on quality of life using
the three-level EuroQol ﬁve-dimensional (EQ-5D-3L) questionnaire
during the 6-month study period. We considered that results of
the Australian clinical study are applicable without adjustment to
the local clinical setting because baseline patient demographic and
disease characteristics appear to be representative of the popula-
tion in whom this technology is being used [4,12].
The cost-utility analysis was conducted for patients aged 12
years or older (see the Utility section later).
Type of Evaluation and Perspective
A clinical trial–based economic evaluation was performed com-
paring the costs and outcomes associated with LGS pump versus
standard pump therapy. The results are reported as an incremen-
tal cost-effectiveness ratio, speciﬁcally as an incremental cost per
quality-adjusted life-year (QALY) gained. The perspective of the
analysis was that of the Australian health care system in seeking
reimbursement of the RT-CGM Enlite sensor for which only direct
health care costs were included. This was a trial-based economic
evaluation so costs and outcomes were not extrapolated beyond
the 6-month clinical trial period and therefore not discounted.
The analysis was not extended beyond the 6-month trial period
because various assumptions from multiple non–evidence-based
sources at present would have been required, which may create
potential uncertainty for a reimbursement decision maker.
Outcomes
Diabetes-related outcomes in the model were as deﬁned in the
clinical study [16]. The primary clinical end point was the
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events. Severe hypoglycemia was deﬁned as hypoglycemic seizure
or coma. Moderate hypoglycemia was deﬁned as a hypoglycemic
event requiring assistance from another person. The rate of
moderate hypoglycemic events has been reported previously
[16]. For purposes of the economic analysis, in focusing on the
patient population who potentially could most beneﬁt from LGS
pump therapy, only the severe hypoglycemia rates were used. The
clinical study [16] reported that LGS pump therapy signiﬁcantly
reduced the number of severe hypoglycemic episodes among
patients to zero compared with those randomized to standard
pump therapy (Table 2).
The severe hypoglycemic event rates for use in the economic
model were converted to 6-monthly probabilities using the
following formula [24]:
Cycle probability¼1ð1ð1esevere hypoglycemic event rateÞÞ6Utility
Given the effect of hypoglycemia on health-related quality of life
in patients with type 1 diabetes [10,25], we calculated quality-of-
life utility scores associated with each treatment based on the
EQ-5D-3L questionnaire instrument. Data were collected at base-
line and at the end of the 6-month comparative study period.
Therefore, values derived from the EQ-5D-3L questionnaire relate
to the quality of life associated with treatment, that is, LGS pump
or standard pump therapy. Utility data, however, were available
only for patients aged 12 years or older because the survey was
administered to parents and carers on behalf of children aged
younger than 12 years. Although there is a validated quality-of-
life instrument for children and adolescents (EQ-5D-Y question-
naire), it is not possible to produce utility values for this
population because the EuroQol group is currently not recom-
mending value sets for the EQ-5D-Y questionnaire [26]. Thus, the
incremental differences in utility valuations calculated in our
study were used only for patients aged 12 years or older.
The utility value to capture acute disutility at the time of a
severe hypoglycemic event is estimated at 0.0033 [27], which
may be considered conservative.
Resources and Costs
Resource use data (non–protocol-driven) over the 6-month study
period were entered into the analysis, along with the costs and
assumptions presented in Table 1 [28–32]. The average daily
insulin dose for each group calculated during the clinical study
was used directly in the model [16]. The clinical study did not
report the number of hypoglycemic episodes that required
emergency medical intervention [16]. Therefore, we searched
the literature for resource use associated with hypoglycemic
episodes in a comparable health care system.
Severe hypoglycemic episodes, deﬁned as events associated with
loss of consciousness or seizure, require medical attention, either in
the community or in the hospital setting. Based on data from the
United Kingdom [33], it is estimated that 76.9% of all severe
hypoglycemic events were managed at home and the remaining
events required emergency medical attention. In terms of resource
utilization for those patients requiring emergency medical atten-
tion, we estimated that 37% involved ambulance service only, 8%
accident and emergency visits, and 55% ambulance and accident
and emergency. We based our resource use estimation on the study
by Leese et al. [34] who reported ﬁgures of 34%, 7%, and 55%
(respectively), yet adjusted so that the overall percentage equaled
100%. In addition, 28% of all severe hypoglycemic events managed
by a health care professional required a hospital admission of 4.423
days per episode [34]. This is reﬂected in the Australian admissionsdata, which estimate that the length of stay for an admission
related to diabetes is 4.429 days [35]. Based on these assumptions,
the average cost of a severe hypoglycemic event managed by the
health care system is $2430.65, ranging from $577.24 for an accident
and emergency visit only to $5684.37 for hospital admission ($121.23
if managed at home). Our analysis, though, may be conservative
because hypoglycemia-related seizures and comas, which are seri-
ous events, would typically be managed by the health care system.
Unit costs for all resources used were obtained from national
statistics or from a national supplier of consumables (Table 1).
Minor differences in costs between suppliers were negligible and
so not assumed to affect the economic evaluation results. The
cost of insulin was derived directly from Pharmaceutical Beneﬁts
Scheme– dispensed prices [28]. We used the dispensed price for
the maximum quantity of Insulin Aspart (PBS item 8571D), the
most commonly used fast-acting insulin, which was $159.37 for
ﬁve vials of 100 units/ml, 10 ml. The cost of glucagon injections
was added to ambulance costs and accident and emergency
visits. For those who attended accident and emergency for a
severe hypoglycemic episode, the cost of a follow-up visit with an
endocrinologist, per standard practice, was added. For those who
were admitted to hospital, the costs of accident and emergency
visits were deducted to avoid double counting in the analysis.
Costs accrue to patients in the economic evaluation as
follows: all patients are treated with either LGS pump or standard
pump therapy; all patients receive ongoing treatment with insu-
lin; and a patient experiencing a severe hypoglycemic event may
be treated either at home or require emergency medical atten-
tion. Emergency medical attention may take the form of an
ambulance call out, a visit to accident and emergency, or both.
A proportion of patients who require emergency medical atten-
tion are admitted to hospital for further treatment.
Costs are reported in Australian dollars (AU $), and values are
current as of February 2013 (Table 1).
Model
The economic model includes a series of stepped analyses whereby
the cohort size in the decision-analytic model is one patient. Step 1
—The trial-based analysis was based directly on the incidence of
severe hypoglycemic events (a key study outcome) during the 6-
month trial period. This included resource costs associated with
insulin pump therapy, RT-CGM, ﬁnger prick testing (SMBG), and
drug costs (Fig. 1). Step 2—In addition to step 1 inputs, this analysis
included broader resource use, that is, costs associated with severe
hypoglycemic events such as hospital admission, accident and
emergency visits, and ambulance call outs. Step 3—We continued
the analysis to include relevant resource use; however, all out-
comes are valued in terms of quality of life. In step 3, we used the
severe hypoglycemia rate only for those aged 12 years or older. For
steps 1 and 2, the cost-effectiveness analysis was reported in terms
of the incremental cost per severe hypoglycemic event avoided
over the 6-month period. For step 3, the results are reported in
terms of QALYs gained over the 6-month period.Analysis
Cohort analysis was used to generate results of the stepped
economic analysis. Rates of severe hypoglycemia were analyzed
as unadjusted incidence rates on the basis of the Poisson
distribution. Incident rates and incident rate difference are
presented with associated 95% exact Poisson conﬁdence intervals
(95% CIs) [16]. Comparisons between EQ-5D-3L questionnaire
scores were conducted using analysis of covariance, adjusting
for baseline score and study group and age group [16]. Other
results are reported as mean values with 95% CIs.
Table 1 – Health care resource use and costs.
Resource item Unit Frequency
of unit
change
Cost per
unit ($)
Source of unit cost LGS
pump
therapy
Standard
pump
therapy
Insulin pump therapy
Standard pump
therapy
1 pump 1/6 y 9500.00 Department of Health and
Aging Prostheses List (item
MC839 or MC840) [29]
X
Sensor-augmented
insulin pump
therapy with LGS
1 pump 1/6 y 9500.00 Department of Health and
Aging Prostheses List (item
MC839 or MC840) [29]
X
Batteries insulin
pump
1 battery 1/5 wk 0.83 National supplier X X
CGM transmitter
and battery
charger
1 transmitter
and charger
1/2 y 499.00 Manufacturer List Price X
Batteries
transmitter
1 battery 1/12 wk 0.83 National supplier X
Enlite glucose
sensor
1 sensor 1/6 d 75.00 Manufacturer List Price X
Infusion set 1 infusion set 1/3 d 14.58 Manufacturer X X
Insulin reservoir 1 reservoir 1/3 d 4.20 Manufacturer X X
Lancets 1 lancet 5/d 0.15 National supplier X X
Glucose test strips 1 test strip 5/d 0.53 Australian Pharmaceutical
Beneﬁts Scheme (item
1503D) [28]
X X
Insulin therapy
Insulin (all
patients)
Units/kg/d 0.794 units/kg 0.03 Australian Pharmaceutical
Beneﬁts Scheme (item
8571D) [28]
X X
Insulin (Z12 y) Units/kg/d 0.793 units/kg 0.03 Australian Pharmaceutical
Beneﬁts Scheme (item
8571D) [28]
X X
Severe hypoglycemic event
Ambulance 1 event 1 607.11 Private Health Insurance
Administration Council [30]
X X
Hospital admission 1 admission 1 5684.37 Australian Institute of Health
and Welfare National
Hospital Cost Data Collection
(2009-2010), weighted
average of K60A and K60B
[31]
X X
Accident and
emergency visit
(nonadmitted)
1 visit 1 456.01 Australian Institute of Health
and Welfare National
Hospital Cost Data Collection
(2009-2010), K60A-B [31]
X X
Glucagon injection 1 injection 1 45.73 Australian Pharmaceutical
Beneﬁts Scheme (item
1449G) [28]
X X
Follow-up visit 1 visit 1 75.50 Australian Medicare Beneﬁts
Schedule (item 116) [32]
X X
LGS, Low Glucose Suspend.
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robustness of the economic evaluation. Inputs including the
severe hypoglycemic event rate, the proportion of events treated
at home versus in hospital, the frequency of insulin pump change,
and the quality-of-life utility calculated from the EQ-5D-3L ques-
tionnaire were altered, using the upper and lower limits of the 95%
CI or, where CIs were not available, by 25% of the mean value.
Analysis of the clinical end points was conducted in SAS for
Windows, version 9.3 (SAS Institute, Inc., Cary, NC), and Stata
version 11.2 (StataCorp, College Station, TX). The economic
evaluation was constructed using Microsoft Excel 2010.Results
The mean costs and effects for sensor-augmented insulin pump
therapy with automated insulin suspension and standard pump
therapy over the study period are presented in Table 2.Outcomes
A signiﬁcantly higher incidence of severe hypoglycemic events
occurred in patients in the standard pump therapy group than in
Patients with type 1 diabetes
and impaired awareness of 
hypoglycemia who are
established users of insulin
 pump therapy
Standard Pump
LGS Pump
Severe hypoglycemic event
 No severe hypoglycemic event
No severe hypoglycemic event
Severe hypoglycemic event
Fig. 1 – Structure of economic model. LGS, Low Glucose Suspend.
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for which zero severe events were reported in the latter group
(see Table 2).
Cost-Effectiveness
The primary measure of cost-effectiveness is the incremental
cost per severe hypoglycemic event avoided over the 6-month
period (in steps 1 and 2), and per QALY (in step 3). In step 1, the
incremental cost effectiveness ratio per event avoided was
$18,257 for all patients and $14,944 for patients aged 12 years
and older. For step 2, the incremental cost-effectiveness ratio was
$17,602 for all patients and $14,289 for patients aged 12 years and
older. In step 3, over the 6-month time horizon, the cost per QALY
gained was $40,803 for patients aged 12 years and older. No cost
per QALY was estimated for patients younger than 12 years
because utility values could not be calculated.
Sensitivity Analysis
Considering all patients and all variables tested, results of the
economic evaluation were most sensitive to the severe hypogly-
cemic event rate. Changing the value of other variables, however,
did not have a substantial effect on the cost-effectiveness ratio
(Table 3). Consequently, the results of this analysis may be
considered robust provided the severe hypoglycemic event rate
observed in the clinical study is maintained. For those aged 12
years or older, a similar conclusion may be drawn, yet in this
group the results were most sensitive to changes in utility values.
Changes to the value of other variables result in only marginal
changes to the cost-effectiveness ratio.Discussion
These data suggest that sensor-augmented insulin pump therapy
with automated insulin suspension is cost-effective in this high-
risk patient population among whom a signiﬁcant clinical beneﬁt
was found. Our assessment of cost-effectiveness is based on
current funding decisions within the Australian health care
setting [36]. To our knowledge, this is the ﬁrst economic assess-
ment of sensor-augmented insulin pump therapy with auto-
mated insulin suspension functionality. Other analyses have
reported the cost-effectiveness of insulin pump therapy com-
pared with multiple daily injections of insulin, both in Australia
[36] and overseas [37]. In the United States, sensor-augmentedinsulin pump therapy (in the absence of automated insulin
suspension) was not found to be cost-effective compared with
multiple daily doses of insulin [38]. In that study, however,
patients with poorly controlled type 1 diabetes were included
and recruitment was not focused on a high-risk (hypoglycemia
unaware) population as in the present analysis.
A key driver of the economic analysis is the severe hypogly-
cemia incident rate difference that signiﬁcantly favored sensor-
augmented insulin pump therapy with LGS. With respect to
quality of life, the clinical study on which our economic analysis
is based found a signiﬁcant difference between the two treatment
groups, favoring sensor-augmented insulin pump therapy with
automated insulin suspension in patient-reported health-related
quality of life as measured directly by the EQ-5D-3L questionnaire
validated instrument (mean difference in utility 0.0733; 95% CI
0.0075–0.1390; P ¼ 0.0289). We are not aware of any other study
reporting a difference in quality of life based on the EQ-5D-3L
questionnaire for insulin pump therapy. This ﬁnding is important
given the need for effective patient self-management of type 1
diabetes in which severe hypoglycemia is a serious and much
feared complication of the condition. Indeed, severe hypoglyce-
mia is considered to be the main barrier to improving and
achieving glycemic targets [5,6]. Others noted: “Any system that
can reduce severity and duration of nocturnal hypoglycemia and,
almost as importantly, reduce fear and anxiety around nocturnal
hypoglycemia may be valuable to patients with type 1 diabetes”
[21]. Furthermore, it has been reported that the fear of hypogly-
cemia is an important determinant of health-related utility—its
magnitude being associated with the frequency and severity of
severe hypoglycemic episodes [39].
Utility values in the clinical study were derived at the time of
a visit and relate solely to the patients’ view of their quality of life
at that time. As such, any acute disutility incurred at the time of
the severe hypoglycemic event was not captured; that is, the
utility questionnaire did not ask for an assessment of quality of
life at the time of a severe hypoglycemic event. The utility value
for a single nonsevere hypoglycemic event, however, has been
estimated by Levy et al. [27] at 0.0033. Although this utility value
is for a nonsevere hypoglycemic event, its use in our analysis
may be conservative because it underestimates the difference in
utilities between having and not having a severe hypoglycemic
event. Hence, the results of the economic evaluation may be
considered conservative.
There is growing evidence that the use of sensor-augmented
insulin pump therapy improves quality of life [40,41], including in
Table 2 – Severe hypoglycemic event rate, EQ-5D questionnaire scores, and results of the economic evaluation.
Clinical study results All patients Patients aged 12 y or older
LGS pump
therapy
Standard pump
therapy
P LGS pump
therapy
Standard pump
therapy
P
Outcome Severe hypoglycemia, rate per 100 patient-months (95% CI) – –
Baseline 2.1 (0.8–4.6) 1.8 (0.6–4.3) 1.1 (0.13–3.95) 2.1 (0.58–5.42)
6 mo 0 (0–2.4) 2.2 (0.5–6.5) 0 (0–3.84) 0.22 (0.27–8.03)
Incident rate difference in severe hypoglycemia from baseline to 6 mo,
rate per 100 patient-months
1.48 (0.26–2.70) 0.00187*
EQ-5D questionnaire index (utility), mean  SD –
Baseline Not done† 0.96  0.07 0.90  0.15
6 mo Not done† 0.97  0.07 0.88  0.16
EQ-5D questionnaire (change from baseline, least squares mean
difference between groups)
Not done† 0.0733
(0.0075–0.1390)
0.0289‡
Economic evaluation All patients Patients aged 12 y or older
LGS pump
therapy A
Standard pump
therapy B
Incremental
A  B‡
LGS pump
therapy A
Standard pump
therapy B
Incremental
A  B§
Step 1 Severe hypoglycemic events 0 0.08607 0.08607 0 0.1052 0.1052
Resource utilization, cost
(AU $)
4381.80 2810.43 1571.36 4431.84 2860.48 1571.36
Step 2 Severe hypoglycemia 0 0.08607 0.08607 0 0.1052 0.1052
Resource utilization, cost
(AU $)
4381.80 2866.78 1515.01|| 4431.84 2929.32 1502.52
Step 3 Quality-adjusted life-years – – – 0.03665 0.00017 0.03682
Resource utilization, cost
(AU $)
4431.84 2929.32 1502.52
ANCOVA, analysis of covariance; EQ-5D, EuroQol ﬁve-dimensional; LGS, Low Glucose Suspend.
* Incident rates from Poisson distribution.
† Utility values for patients aged younger than 12 y cannot be calculated.
‡ Results from ANCOVA adjusted for baseline score, treatment group, and age group.
§ Because the analytic output is in terms of hypoglycemic events avoided, itself a negative term, the negative signs for hypoglycemic event differences are removed for reporting.
|| Differences in incremental costs and the difference between treatment arms are due to rounding.
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Table 3 – Sensitivity analysis.
Sensitivity analysis Incremental outcomes Incremental cost ($) ICER ($)
All patients—Outcome reported in terms of severe hypoglycemic events avoided; ICER is cost per event-free year, base case is $17,602
Insulin pump—4 y 0.08607 1515.01 17,602
Insulin pump—8 y 0.08607 1515.01 17,602
Hypoglycemic event rate—0.3 0.01784 1559.68 87,431
Hypoglycemic event rate—2.7 0.14956 1473.45 9,852
Home vs. hospital—25% 0.08607 1476.80 17,158
Home vs. hospital—þ25% 0.08607 1553.23 18,046
Patients Z 12 y—Outcome reported in terms of QALY gained; base case is $40,803
Insulin pump—4 y 0.03682 1502.52 40,803
Insulin pump—8 y 0.03682 1502.52 40,803
Hypoglycemic event rate—0.15133 0.03666 1567.58 42,760
Hypoglycemic event rate—3.5525 0.03697 1445.68 39,108
Home vs. hospital—25% 0.03682 1455.84 39,536
Home vs. hospital— þ25% 0.03682 1549.21 42,071
Utility—0.0075 0.00392 1502.52 382,954
Utility—0.1390 0.06967 1502.52 21,565
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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the LGS functionality. To our knowledge, this is the ﬁrst time
patient-reported health-related quality of life, as measured by
EQ-5D-3L questionnaire scores, has been reported that found a
signiﬁcant utility gain for sensor-augmented pump therapy with
automated insulin suspension.
In this patient population, which is less sensitive to detecting
hypoglycemia, the fear of hypoglycemia is likely to be more
extreme than in the general population with type 1 diabetes
[43]. The conservative approach taken in this model did not
quantify the reduction in fear of hypoglycemia events, and
therefore may have underestimated the cost utility of sensor-
augmented insulin pump therapy. It should be noted that this is
not an efﬁcacy study. It is a realistic study approximating real-life
clinical practice in which patients and health providers are aware
of treatments and behave accordingly.
Our economic analysis of treatment options for patients using
insulin pump therapy for type 1 diabetes is based directly on
randomized study data. Because the data were collected in a
naturalistic setting, it is considered to be relevant to clinical
practice and therefore applicable to an important percentage of
high-risk patients with type 1 diabetes.
Our analysis also shows that the increased cost of treatment
using sensor-augmented insulin pump therapy with automated
insulin suspension approach is partially offset by a reduction in
costs associated with medical treatment required for severe
hypoglycemic events.
Limitations of our analysis include the small study size and
follow-up time of 6 months, notwithstanding that type 1 diabetes
is a chronic condition for which lifelong therapy is required.
Given the assumptions required to extend the time horizon and
that the randomized clinical study collected “hard” outcomes in
rigorously deﬁning a severe hypoglycemic event as hypoglycemic
seizure or coma, this approach was appropriate. Because this
analysis was conducted from a health care system perspective,
indirect costs such as lost productivity and out-of-pocket
expenses associated with a hospitalization have not been
included. We thus possibly underestimated the cost of severe
hypoglycemic episodes and hence the cost-effectiveness of
sensor-augmented pump therapy with automated insulin sus-
pension if a broader societal perspective was taken. Furthermore,
utility values derived from the EQ-5D-3L questionnaire (Table 2)
likely underestimate the full value of this technology because
data reﬂect the patient’s perception of quality of life at the twovisits at which quality of life was measured. The economic
model, however, captured the acute disutility associated with a
severe hypoglycemic event, and therefore more completely
quantiﬁes the cost utility in this population of combining sensors
with an insulin pump that has automated insulin suspension.
Our analysis was limited to severe hypoglycemic events, for
which there are hard clinical end points (loss of consciousness
or seizure), and represents those with the greatest clinical need.
We could have included moderate events, which may also impair
utility, and by not doing so may have produced a conservative
estimate. Finally, some may argue against standard pump ther-
apy without CGM as the appropriate choice of comparator in this
patient population. In Australia, experts recommend that RT-
CGM be considered in patients who are hypoglycemia unaware
[2,13,14], although uptake is poor. This may reﬂect the lack of
reimbursement for sensors in the Australian market. Therefore,
we used standard pump therapy as our comparator because this
is currently the “standard of care” in Australia.
The results of our study are applicable to the Australian type 1
diabetes subpopulation with impaired hypoglycemia awareness.
Because of the different health care systems in different coun-
tries, results may not be readily generalizable to other health care
settings without adapting cost consequences dependent on local
medical practice. This may also help explain the difference in
results between our analysis and the US study [38].Conclusions
The patients in the analysis represent a population with a high
clinical need who are continuously exposed to an increased risk
of severe clinical consequences associated with frequent medical
intervention and potential death. The importance of providing
access to sensor-augmented insulin pump therapy with auto-
mated insulin suspension that signiﬁcantly reduces severe
hypoglycemic episodes has been previously demonstrated in
patients with type 1 diabetes and impaired hypoglycemia aware-
ness through a signiﬁcant reduction in severe hypoglycemic
episodes [44].
The economic analysis of this technology aims to inform
third-party payers and decision makers that this is also a cost-
effective treatment. From the Australian experience, sensor-
augmented insulin pump therapy with automated insulin
suspension may be considered a cost-effective alternative to
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 6 1 – 5 6 9568standard pump therapy in a hypoglycemia unaware population
with type 1 diabetes. The increases in costs associated with this
technology are partially offset by reduced episodes of severe
hypoglycemia and associated resource use.
Future research should assess the clinical and quality-of-life
outcomes of sensor-augmented insulin pump therapy with auto-
mated insulin suspension in a larger randomized clinical trial of
longer duration. In particular, consideration should be given to
other high-risk patient populations (such as patients with severe
recurrent hypoglycemia, or frequent nocturnal events) who may
beneﬁt from this technology, which represents an important step
toward a fully automated closed loop “artiﬁcial pancreas” system.Acknowledgments
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